158 related articles for article (PubMed ID: 28872544)
1. Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect?
Kwee SA; Lim J; Coel MN
Clin Nucl Med; 2017 Nov; 42(11):868-871. PubMed ID: 28872544
[TBL] [Abstract][Full Text] [Related]
2. Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?
García Vicente AM; Soriano Castrejón Á; Alvarez Cabellos R; Sanchez Gil B; Mohedano Mohedano N
Clin Nucl Med; 2017 Oct; 42(10):761-765. PubMed ID: 28806246
[TBL] [Abstract][Full Text] [Related]
3. 223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient With Castration-Resistant Metastatic Prostate Cancer.
Wang J; Kuker R; Serafini A
Clin Nucl Med; 2020 Nov; 45(11):e486-e488. PubMed ID: 32657864
[TBL] [Abstract][Full Text] [Related]
4. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
Lee J; Sato MM; Coel MN; Lee KH; Kwee SA
J Nucl Med; 2016 Jul; 57(7):1058-64. PubMed ID: 26912444
[TBL] [Abstract][Full Text] [Related]
5. Baseline
García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
[TBL] [Abstract][Full Text] [Related]
6. The potential of
Murray I; Chittenden SJ; Denis-Bacelar AM; Hindorf C; Parker CC; Chua S; Flux GD
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1832-1844. PubMed ID: 28612079
[TBL] [Abstract][Full Text] [Related]
7. The Relationship Between Total Lesion Activity on
Filippi L; Basile P; Schillaci O; Bagni O
Cancer Biother Radiopharm; 2020 Aug; 35(6):398-403. PubMed ID: 32109140
[TBL] [Abstract][Full Text] [Related]
8. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
Vija Racaru L; Sinigaglia M; Kanoun S; Ben Bouallègue F; Tal I; Brillouet S; Bauriaud-Mallet M; Zerdoud S; Dierickx L; Vallot D; Caselles O; Gabiache E; Pascal P; Courbon F
Nucl Med Commun; 2018 Jul; 39(7):672-679. PubMed ID: 29790867
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223.
Scalzi P; Baiocco C; Genovese S; Trevisan A; Sirotova Z; Poti C
Urologia; 2017 Feb; 84(1):61-64. PubMed ID: 27911459
[TBL] [Abstract][Full Text] [Related]
10. Uptake of Radium-223 Dichloride and Early [
Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen flare induced by
Castello A; Macapinlac HA; Lopci E; Santos EB
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
[TBL] [Abstract][Full Text] [Related]
12. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
Donners R; Tunariu N; Tovey H; Hall E; Chua S; Cook G; Du Y; Blackledge MD; Parker CC; Koh DM
Eur Radiol; 2024 Feb; 34(2):1146-1154. PubMed ID: 37615760
[TBL] [Abstract][Full Text] [Related]
13.
Dizdarevic S; Jessop M; Begley P; Main S; Robinson A
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419
[TBL] [Abstract][Full Text] [Related]
14. Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy.
Bode A; Rahbar K; Konnert J; Bögemann M; Stegger L
Clin Nucl Med; 2016 Dec; 41(12):951-952. PubMed ID: 27749411
[TBL] [Abstract][Full Text] [Related]
15. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA
Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640
[TBL] [Abstract][Full Text] [Related]
16. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
McNamara MA; Oyekunle T; Chin BB; Oldan J; Anand A; Ritz M; Shantzer L; Anand M; Armstrong AJ; George DJ
Prostate; 2019 Jul; 79(10):1106-1116. PubMed ID: 31045266
[TBL] [Abstract][Full Text] [Related]
17. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Jadvar H; Challa S; Quinn DI; Conti PS
Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM
J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of
Quaquarini E; D'Ambrosio D; Sottotetti F; Gallivanone F; Hodolic M; Baiardi P; Palumbo R; Vellani C; Canevari C; Bernardo A; Castiglioni I; Porta C; Trifirò G
Contrast Media Mol Imaging; 2019; 2019():4325946. PubMed ID: 31049043
[TBL] [Abstract][Full Text] [Related]
20. Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
Iizuka J
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():16-23. PubMed ID: 30489033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
